BRAF and melorheostosis: One patient with refractory MEL to immunotherapy and BRAF-MEK inhibition was of special interest due to the mutation spectrum detected in tissue and cfDNA (Fig. 6 schematically depicts the clinical course of MEL003.1, including genotyping of tissue and plasma).